Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Korean health officials track real-world safety of new PNH combo therapy

NCT ID NCT07457151

First seen Mar 22, 2026 · Last updated May 23, 2026 · Updated 5 times

Summary

This study monitors the safety and effectiveness of Danicopan when used alongside standard PNH treatments (ravulizumab or eculizumab) in routine Korean medical practice. It involves 8 participants and aims to confirm known side effects or detect new ones, as well as measure changes in blood markers like hemoglobin. The study is for patients already prescribed this combination by their doctor.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Busan, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Daegu, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Hwasun-gun, South Korea

  • Research Site

    RECRUITING

    Seoul, South Korea

  • Research Site

    NOT_YET_RECRUITING

    Seoul, South Korea

Conditions

Explore the condition pages connected to this study.